GIS.DE Earnings — Gilead Sciences, Inc.
XETRA
Updated
When is GIS.DE's next earnings date?
Gilead Sciences, Inc. (GIS.DE) has not announced its next earnings date yet. Its most recent earnings report was on Thursday, October 29, 2026.
How did GIS.DE do in its last earnings report?
In its most recent report on Oct 29, 2026, Gilead Sciences, Inc. posted EPS of $2.55 versus the $1.94 estimate, a beat of 31.4%. Revenue was $8.30B against a $6.89B estimate.
How much does GIS.DE stock move after earnings?
GIS.DE beat EPS estimates in 2 of its last 2 reported quarters.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical innovator dedicated to the research, development, and global commercialization of medicines that address significant unmet medical needs across the United States, Europe, and other international regions. Its extensive product lineup includes leading treatments for HIV/AIDS, such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla. For COVID-19, the company provides Veklury, an injectable therapy for intravenous administration. Gilead also offers a robust portfolio of drugs combating various liver diseases, specifically Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, it supplies therapeutic solutions for patients with hematological, oncological, and cell-based conditions, including Yescarta, Tecartus, Trodelvy, and Zydelig. Beyond these, its offerings extend to Letairis, an oral medication for pulmonary arterial hypertension; Ranexa, another oral formulation for chronic angina; and AmBisome, a liposomal agent designed to treat serious invasive fungal infections. Incorporated in 1987 and headquartered in Foster City, California, Gilead Sciences actively engages in collaboration agreements with various entities, such as Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc.
🤖 AI Earnings Analysis
General Mills posted a strong beat, with $2.55 EPS versus $1.94 expected and $8.3B revenue versus $6.9B; reported 240% sales growth and 28.9% margin look exceptionally robust.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | 1.94 | 2.55 | +31.44% | $8.30B | ✅ Beat | — | — | — | |
| 2026-08-04 | -6.35 | -5.91 | — | $6.83B | ✅ Beat | — | — | — |
Showing last 2 quarters.
Revenue by segment & region
By segment
Q3 FY25 · $6.61B total
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| Products, Other HIV | 79.8% | $5.28B | — |
| Cell Therapy Products, Total Cell Therapy Product Sales | 7.8% | $515.0M | — |
| Trodelvy | 5.4% | $357.0M | — |
| Veklury | 4.2% | $277.0M | — |
| Other Products, Total Other product sales | 2.8% | $184.0M | — |
By region
Q3 FY25 · $7.77B total
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| UNITED STATES | 68.0% | $5.28B | — |
| Europe | 20.0% | $1.55B | — |
| Other International | 12.0% | $933.0M | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.